Evorel Conti patches Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

evorel conti patches

theramex hq uk ltd - norethisterone acetate; estradiol - transdermal patch - 170microgram/24hour ; 50microgram/24hour

Evorel Conti 50/170 micrograms per 24 hours Transdermal Patch Īrija - angļu - HPRA (Health Products Regulatory Authority)

evorel conti 50/170 micrograms per 24 hours transdermal patch

janssen sciences ireland uc - estradiol hemihydrate; norethisterone acetate - transdermal patch - 50 microg/24h +170 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol, combinations

EVOREL SEQUI Izraēla - angļu - Ministry of Health

evorel sequi

j-c health care ltd - estradiol as hemihydrate; estradiol as hemihydrate; norethisterone acetate - patches - estradiol as hemihydrate 3.2 mg; norethisterone acetate 11.2 mg; estradiol as hemihydrate 3.2 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy for the relief of menopausal symptoms.

NOVOFEM Izraēla - angļu - Ministry of Health

novofem

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - film coated tablets - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.the experience treating women older than 65 years is limited.

EVIANA Izraēla - angļu - Ministry of Health

eviana

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - film coated tablets - estradiol as hemihydrate 0.5 mg; norethisterone acetate 0.1 mg - estradiol, combinations - estradiol, combinations - eviana is indicated for women who have a uterus for the: treatment of moderate to severe vasomotor symptoms associated with menopause. prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered .the experience treating women older than 65 years is limited .

Evorel Sequi Malta - angļu - Medicines Authority

evorel sequi

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - estradiol hemihydrate, norethisterone acetate - transdermal patch - estradiol hemihydrate 3.2 milligram(s) ; norethisterone acetate 11.2 milligram(s) - sex hormones and modulators of the genital system

ESTRADIOL / NORETHINDRONE ACETATE- estradiol and norethindrone acetate tablet, film coated Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

estradiol / norethindrone acetate- estradiol and norethindrone acetate tablet, film coated

physicians total care, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: - treatment of moderate to severe vasomotor symptoms associated with menopause. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. the mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400-800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. estradiol/norethindrone acetate tablets 1.0 mg/0.5 mg is also in